Patología Intestinal 8.- Karamanolis G, Vanuytsel T, Sifrim S 8 D, Bisschops R, Arts J, Caenepeel P, et al. Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy. Dig Dis Sci 2008; 53: 2387-93. 9.- Gasiorowska A, Navarro-Rodríguez T, Wendel C, Krupinski E, Perry ZH, Koenig K, et al. Comparison of the degree of duodenogastroesophageal reflux and acid reflux between patients who failed to respond and those who were successfully treated with a proton pump inhibitor once daily. Am J Gastroenterol 2009; 104: 2005-13. 10.- Vela MF, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001; 120: 1599-606. 11.- Karamanolis G, Stevens W, Vos R, Tack J, Clave P, Sifrim D. Oesophageal tone and sensation in the transition zone between proximal striated and distal smooth muscle oesophagus. Neurogastroenterol Motil 2008; 20: 291- 7. Diagn óstic o y manej o en sínt oma s de ref luj o refractari o - H. Monrroy B. et al. 12.- Hirano I, Richter JE, Practice Parameters Committee of the American College of G. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007; 102: 668-85. 13.- Hemmink GJ, Bredenoord AJ, Weusten BL, Monkelbaan JF, Timmer R, Smout AJ. Esophageal pH-impedance monitoring in patients with therapyresistant reflux symptoms: ‘on’ or ‘off’ proton pump inhibitor? Am J Gastroenterol 2008; 103: 2446-53. 14.- Mainie I, Tutuian R, Agrawal A, Adams D, Castell DO. Combined multichannel intraluminal impedance-pH monitoring to select patients with persistent gastrooesophageal reflux for laparoscopic Nissen fundoplication. Br J Surg 2006; 93: 1483-7. 15.- Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166: 965-71. 16.- Dickman R, Boaz M, Aizic S, Beniashvili Z, Fass R, Niv Y. Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded. J Neurogastroenterol Motil 2011; 17: 387- 94. 17.- Moayyedi P, Armstrong D, Hunt RH, Lei Y, Bukoski M, White RJ. The gain in quality-adjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: EncomPASS-a cluster-randomized trial. Am J Gastroenterol 2010; 105: 2341-6. 18.- Manabe N, Haruma K, Ito M, Takahashi N, Takasugi H, Wada Y, et al. Efficacy of adding sodium alginate to omeprazole in patients with nonerosive reflux disease: a randomized clinical trial. Dis Esophagus 2012; 25: 373-80. 19.- Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther 2001; 15: 1351-6. 20.- Li S, Shi S, Chen F, Lin J. The effects of baclofen for the treatment of gastroesophageal reflux disease: a metaanalysis of randomized controlled trials. Gastroenterol Res Pract 2014; 2014: 307805. Gastroenterol. latinoam 2016; Vol 27, S upl Nº 1: S 5-S 8
Gastro_3
To see the actual publication please follow the link above